FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205216230> ?p ?o ?g. }

• W3205216230 abstract "Abstract Objective To evaluate role of genetic factors (polymorphisms of ADRB1 gene (Arg389Gly, rs1801253) and ACE gene (I/D, rs4343) for effectiveness assessment of β-blocker (carvedilol) and angiotensin-converting enzyme inhibitor (enalapril) therapy in women with anthracycline- induced cardiotoxicity during 12-month follow-up period. Methods A total of 82 women, median age of 45.0 (42.0; 50.0) years with anthracycline-induced cardiotoxicity and without prior cardiovascular diseases were enrolled in the study. All patients received chemotherapy for the treatment of breast cancer included a combination of doxorubicin and cyclophosphamide, or combination of doxorubicin, cyclophosphamide and docetaxel. The cumulative dose of doxorubicin was 300–360 mg/m2. Criteria for the development of cardiotoxicity were a decrease in the left ventricle ejection fraction (LVEF) at the 12 months after chemotherapy completion by &gt;10%, the development of heart failure (HF) with symptoms and clinical signs, and NT-proBNP levels ≥125 pg/mL. Echocardiography and serum levels of NT-proBNP were performed at baseline and at 12 months after enrollment. Average up-titrated dosage of carvedilol was 50 (25; 50) mg per day and enalapril was 10 (10; 20) mg per day. Evaluation of gene polymorphisms of ADRB1 gene and ACE gene were carried out by polymerase chain reaction at baseline before treatment initiation. Results The baseline LVEF, end-systolic and end-diastolic dimension indexes, NT-proBNP levels, 6-minute walk test distance did not differ among patients with different genotypes of ADRB1 and ACE genes. However, carriers of T/T genotype of ADRB1 gene had a significant increasing in LVEF (&lt;0.001) by 11% from 50.0 (48.0; 51.0) to 56.0 (53.0; 57.0)% and decreasing in end-systolic dimension index (p&lt;0.001) by 27.7% and end-systolic dimension index (p&lt;0.001) by 6% within 12 months of follow-up period. The levels of NT-proBNP decreased (p=0.001) by 34.2% from 327.5 (260.1; 381.8) to 213.5 (195.3; 256.7) pg/mL and 6-minute walk test distance increased (0.008) by 10%. Carriers of G/G genotype of ACE gene had the same benefits from this therapy: LVEF (&lt;0.001) increased by 6.5% from 50.5 (47.0; 51.0) to 54.0 (50.0; 57.0)%, end-systolic dimension index (p&lt;0.001) decreased by 5.3% and end-systolic dimension index (p&lt;0.001) by 3% within 12 months of follow-up period. The levels of NT-proBNP decreased (p=0.005) by 20.3 from 314.1 (279.6; 372.9) to 249.9 (197.3; 267.8) pg/mL and 6-minute walk test distance increased (0.008) by 5%. Carriers of other genotypes had decreasing in LVEF, increasing in LV dimensions and NT-proBNP, and further progression of HF. Conclusion Our data suggest that evaluation of gene polymorphisms of ADRB1 (Arg389Gly, rs1801253) and ACE gene (I/D, rs4343) can be recommended before treatment initiation of anthracycline- induced cardiotoxicity in women without prior cardiovascular diseases to determine who will benefit of carvedilol and enalapril therapy. FUNDunding Acknowledgement Type of funding sources: None." @default.
• W3205216230 created "2021-10-25" @default.
• W3205216230 creator A5014973049 @default.
• W3205216230 creator A5021407222 @default.
• W3205216230 creator A5029866989 @default.
• W3205216230 creator A5040423079 @default.
• W3205216230 creator A5068314096 @default.
• W3205216230 creator A5080022172 @default.
• W3205216230 creator A5086044721 @default.
• W3205216230 creator A5089504204 @default.
• W3205216230 date "2021-10-01" @default.
• W3205216230 modified "2023-10-11" @default.
• W3205216230 title "Pharmacogenetics of therapy effectiveness for anthracycline-induced cardiotoxicity" @default.
• W3205216230 doi "https://doi.org/10.1093/eurheartj/ehab724.2861" @default.
• W3205216230 hasPublicationYear "2021" @default.
• W3205216230 type Work @default.
• W3205216230 sameAs 3205216230 @default.
• W3205216230 citedByCount "0" @default.
• W3205216230 crossrefType "journal-article" @default.
• W3205216230 hasAuthorship W3205216230A5014973049 @default.
• W3205216230 hasAuthorship W3205216230A5021407222 @default.
• W3205216230 hasAuthorship W3205216230A5029866989 @default.
• W3205216230 hasAuthorship W3205216230A5040423079 @default.
• W3205216230 hasAuthorship W3205216230A5068314096 @default.
• W3205216230 hasAuthorship W3205216230A5080022172 @default.
• W3205216230 hasAuthorship W3205216230A5086044721 @default.
• W3205216230 hasAuthorship W3205216230A5089504204 @default.
• W3205216230 hasBestOaLocation W32052162301 @default.
• W3205216230 hasConcept C104317684 @default.
• W3205216230 hasConcept C121608353 @default.
• W3205216230 hasConcept C126322002 @default.
• W3205216230 hasConcept C135763542 @default.
• W3205216230 hasConcept C143998085 @default.
• W3205216230 hasConcept C164705383 @default.
• W3205216230 hasConcept C185592680 @default.
• W3205216230 hasConcept C27016395 @default.
• W3205216230 hasConcept C2775940317 @default.
• W3205216230 hasConcept C2776694085 @default.
• W3205216230 hasConcept C2776802502 @default.
• W3205216230 hasConcept C2778198053 @default.
• W3205216230 hasConcept C2778233292 @default.
• W3205216230 hasConcept C2780591200 @default.
• W3205216230 hasConcept C2781303535 @default.
• W3205216230 hasConcept C530470458 @default.
• W3205216230 hasConcept C55493867 @default.
• W3205216230 hasConcept C55775858 @default.
• W3205216230 hasConcept C71924100 @default.
• W3205216230 hasConcept C78085059 @default.
• W3205216230 hasConcept C84393581 @default.
• W3205216230 hasConcept C98274493 @default.
• W3205216230 hasConceptScore W3205216230C104317684 @default.
• W3205216230 hasConceptScore W3205216230C121608353 @default.
• W3205216230 hasConceptScore W3205216230C126322002 @default.
• W3205216230 hasConceptScore W3205216230C135763542 @default.
• W3205216230 hasConceptScore W3205216230C143998085 @default.
• W3205216230 hasConceptScore W3205216230C164705383 @default.
• W3205216230 hasConceptScore W3205216230C185592680 @default.
• W3205216230 hasConceptScore W3205216230C27016395 @default.
• W3205216230 hasConceptScore W3205216230C2775940317 @default.
• W3205216230 hasConceptScore W3205216230C2776694085 @default.
• W3205216230 hasConceptScore W3205216230C2776802502 @default.
• W3205216230 hasConceptScore W3205216230C2778198053 @default.
• W3205216230 hasConceptScore W3205216230C2778233292 @default.
• W3205216230 hasConceptScore W3205216230C2780591200 @default.
• W3205216230 hasConceptScore W3205216230C2781303535 @default.
• W3205216230 hasConceptScore W3205216230C530470458 @default.
• W3205216230 hasConceptScore W3205216230C55493867 @default.
• W3205216230 hasConceptScore W3205216230C55775858 @default.
• W3205216230 hasConceptScore W3205216230C71924100 @default.
• W3205216230 hasConceptScore W3205216230C78085059 @default.
• W3205216230 hasConceptScore W3205216230C84393581 @default.
• W3205216230 hasConceptScore W3205216230C98274493 @default.
• W3205216230 hasIssue "Supplement_1" @default.
• W3205216230 hasLocation W32052162301 @default.
• W3205216230 hasOpenAccess W3205216230 @default.
• W3205216230 hasPrimaryLocation W32052162301 @default.
• W3205216230 hasRelatedWork W11627380 @default.
• W3205216230 hasRelatedWork W17695891 @default.
• W3205216230 hasRelatedWork W18589541 @default.
• W3205216230 hasRelatedWork W19199159 @default.
• W3205216230 hasRelatedWork W2011212 @default.
• W3205216230 hasRelatedWork W20153909 @default.
• W3205216230 hasRelatedWork W6111848 @default.
• W3205216230 hasRelatedWork W6284278 @default.
• W3205216230 hasRelatedWork W9611164 @default.
• W3205216230 hasRelatedWork W9675859 @default.
• W3205216230 hasVolume "42" @default.
• W3205216230 isParatext "false" @default.
• W3205216230 isRetracted "false" @default.
• W3205216230 magId "3205216230" @default.
• W3205216230 workType "article" @default.